Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Galimberti

Showing results (11-20 of 526) with videos related to

Pageof 53
Sort By:
Journal of Neurology|June 23, 2012
Progress in multiple sclerosis research in the last yearDaniela Galimberti, Elio Scarpini
Current Aging Science|March 20, 2010
Treatment of Alzheimer's disease: symptomatic and disease-modifying approachesDaniela Galimberti, Elio Scarpini
Frontiers in Neurology|April 27, 2012
Genetics of frontotemporal lobar degenerationDaniela Galimberti, Elio Scarpini
Expert Opinion on Emerging Drugs|January 29, 2016
Emerging amyloid disease-modifying drugs for Alzheimer's diseaseDaniela Galimberti, Elio Scarpini
Frontiers in Bioscience (Scholar Edition)|January 4, 2011
Inflammation and oxidative damage in Alzheimer's disease: friend or foe?Daniela Galimberti, Elio Scarpini
Journal of Neural Transmission (Vienna, Austria : 1996)|April 25, 2012
Clinical phenotypes and genetic biomarkers of FTLDDaniela Galimberti, Elio Scarpini
Expert Opinion on Investigational Drugs|November 26, 2016
Pioglitazone for the treatment of Alzheimer's diseaseDaniela Galimberti, Elio Scarpini
Drug Design, Development and Therapy|December 20, 2013
Disease-modifying drugs in Alzheimer's diseaseLaura Ghezzi, Elio Scarpini, Daniela Galimberti
Expert Review of Neurotherapeutics|April 28, 2005
Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatmentsDaniela Galimberti, Nereo Bresolin, Elio Scarpini
Expert Review of Neurotherapeutics|May 26, 2018
Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementiaChiara Fenoglio, Elio Scarpini, Daniela Galimberti
Pageof 53

Showing results (11-20 of 526) with videos related to

Sort By:
Pageof 53
Journal of Neurology|June 23, 2012
Progress in multiple sclerosis research in the last yearDaniela Galimberti, Elio Scarpini
Current Aging Science|March 20, 2010
Treatment of Alzheimer's disease: symptomatic and disease-modifying approachesDaniela Galimberti, Elio Scarpini
Frontiers in Neurology|April 27, 2012
Genetics of frontotemporal lobar degenerationDaniela Galimberti, Elio Scarpini
Expert Opinion on Emerging Drugs|January 29, 2016
Emerging amyloid disease-modifying drugs for Alzheimer's diseaseDaniela Galimberti, Elio Scarpini
Frontiers in Bioscience (Scholar Edition)|January 4, 2011
Inflammation and oxidative damage in Alzheimer's disease: friend or foe?Daniela Galimberti, Elio Scarpini
Journal of Neural Transmission (Vienna, Austria : 1996)|April 25, 2012
Clinical phenotypes and genetic biomarkers of FTLDDaniela Galimberti, Elio Scarpini
Expert Opinion on Investigational Drugs|November 26, 2016
Pioglitazone for the treatment of Alzheimer's diseaseDaniela Galimberti, Elio Scarpini
Drug Design, Development and Therapy|December 20, 2013
Disease-modifying drugs in Alzheimer's diseaseLaura Ghezzi, Elio Scarpini, Daniela Galimberti
Expert Review of Neurotherapeutics|April 28, 2005
Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatmentsDaniela Galimberti, Nereo Bresolin, Elio Scarpini
Expert Review of Neurotherapeutics|May 26, 2018
Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementiaChiara Fenoglio, Elio Scarpini, Daniela Galimberti
Pageof 53